DecisionPoint Financial’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-1,000
Closed -$88.4K 672
2025
Q2
$88.4K Hold
1,000
0.02% 65
2025
Q1
$91.1K Hold
1,000
0.03% 59
2024
Q4
$86.3K Hold
1,000
0.03% 61
2024
Q3
$95K Hold
1,000
0.03% 59
2024
Q2
$93.1K Hold
1,000
0.03% 59
2024
Q1
$86.8K Hold
1,000
0.03% 59
2023
Q4
$81.4K Hold
1,000
0.03% 54
2023
Q3
$79.9K Hold
1,000
0.04% 44
2023
Q2
$78.8K Hold
1,000
0.04% 46
2023
Q1
$77.6K Hold
1,000
0.04% 46
2022
Q4
$77.7K Buy
+1,000
New +$73.8K 0.05% 43

Other funds holding PPH

DecisionPoint Financial's PPH Position: Q3 2025 in Review

DecisionPoint Financial sold out of VanEck Pharmaceutical ETF (PPH) in Q3 2025, closing a stake of 1,000 shares — an estimated $88.4K sold.

DecisionPoint Financial first reported a position in PPH in Q4 2022 and held it in 11 quarters. The position peaked at $95K in Q3 2024. 127 funds tracked by Wall St. Rank hold PPH as of Q3 2025.

  • DecisionPoint Financial reported no remaining VanEck Pharmaceutical ETF position as of Q3 2025 after selling out during the quarter.
  • DecisionPoint Financial sold 1,000 VanEck Pharmaceutical ETF shares in Q3 2025, an estimated $88.4K.
  • DecisionPoint Financial first reported a position in VanEck Pharmaceutical ETF in Q4 2022 and held it in 11 quarters.
  • DecisionPoint Financial's VanEck Pharmaceutical ETF position peaked at $95K in Q3 2024.
  • 127 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2025.

Based on DecisionPoint Financial's 13F filing for Q3 2025, filed 10 Nov 2025.